CytoDyn Inc. (OTCMKTS: CYDY) has been going through a massive consolidation since March 30, 2021 after they announced a statistically significant 82% reduction in mortality at day 14. The great news fell on deaf ears at the FDA who instead of issuing an EUA lashed back at shareholders who were badgering them for approval with an FDA statement that sent the stock careening south.
On May 24, 2021, just as the stock was recovering, the 13-D group known as Advancing Leronlimab, took a very peculiar tactic of bashing management and in doing so aligned themselves with the shorts. After the top-line data announcement at the end of March, the shorts and the 13-D group have been controlling the narrative.
Shorts have made impressive returns using the tactics of spreading Fear, Uncertainty, and Doubt (FUD) amongst the longs and 13-D group. Their latest tactic is to paint a picture that there is a new SEC investigation mentioned in the latest 10-K filing. Unfortunately for the shorts this is a complete fabrication.
What is so sad is that there appear to be investors posting on the message boards that are actually falling for this FUD and wanting to vote the Advancing Leronlimab (13-D) proxy.
On July 29th, 2021 the stock traded only 604,000 shares which was the lowest volume day since COVID-19 was first discovered. Inflection points come at the end of consolidation periods and the shorts know this and started an attack this weekend. They started with invading the message boards and then an article in The Oregonian. Notably absent from their attacks is the shorts leader from Stat News, Adam Feuerstein, who decided to take a sabbatical for the month of August.